Novo Nordisk A S (NONOF) stock
NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$38.24−0.60 (-1.53%)
Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –
Novo Nordisk A S enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Novo Nordisk A S's enterprise value was $196.01B on Nov 3, 2026, against $234.73B a year earlier. Over the last 5 years it ranged from $181.28B to $639.08B, with a median of $316.89B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 3, 2026 | $196.01B | -18.9% |
| 2025 | Dec 31, 2025 | $241.71B | -37.4% |
| 2024 | Dec 31, 2024 | $386.13B | -17.4% |
| 2023 | Dec 29, 2023 | $467.69B | +47.6% |
| 2022 | Dec 30, 2022 | $316.89B | +20.0% |
| 2021 | Dec 31, 2021 | $264.05B | +59.0% |
| 2020 | Dec 31, 2020 | $166.09B | +20.2% |
| 2019 | Dec 31, 2019 | $138.13B | +23.6% |
| 2018 | Dec 31, 2018 | $111.79B | -16.0% |
| 2017 | Dec 29, 2017 | $133.10B | +47.6% |
| 2016 | Dec 30, 2016 | $90.19B | – |
See a number that looks wrong?